Navigation Links
Cancer-causing virus exploits key cell-survival proteins
Date:2/22/2011

COLUMBUS, Ohio A cancer-causing retrovirus exploits key proteins in its host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) and Ohio State's College of Veterinary Medicine.

The human T-lymphotropic virus type-1 (HTLV-1), which causes adult T-cell leukemia and lymphoma, produces a protein called p30 that is essential for the retrovirus to establish an infection. This study found that this viral protein targets two important cell proteins: ATM, a key player in a cell's response to DNA damage, and REG-gamma, which marks proteins within the cell for destruction.

"Our findings suggest that the p30 viral protein prolongs the survival of host cells through this interaction with ATM and REG-gamma, and the longer a virus-infected cell survives, the better chance the virus has to spread, " says principal investigator Michael Lairmore, DVM, PhD, professor of veterinary biosciences and associate director for shared resources at the OSUCCC James.

The findings were published recently in the Journal of Biological Chemistry.

An estimated 20 million people worldwide are infected by HTLV-1, and about five percent of them will develop adult T-cell leukemia or lymphoma, or one of a variety of inflammatory disorders.

Lairmore and his colleagues used cell lines and a variety of biochemical assays to identify cellular binding partners of p30. They discovered the following:

  • p30 specifically binds to cellular ATM (ataxia-telangiectasia mutated), a key regulator of DNA damage responses and cell cycle control, and to REG-gamma, a nuclear proteasome activator.
  • Under stressful conditions, p30 levels are associated with lower ATM levels and increased cell survival.
  • The expression of p30 ch
    '/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Cancer-causing bacterium targets tumor-suppressor protein
2. IU researchers target vascular disease linked to cancer-causing gene mutation
3. Cancer-causing protein can also help fight the tumors it causes
4. Link between unexploded munitions in oceans and cancer-causing toxins determined
5. Cancer-causing gene discovery suggests new therapies
6. Macavity wasnt there! How absent reoviruses kill cancer
7. Brandeis study shows economic impact of dengue virus in Americas
8. Caffeine energizes cells, boosting virus production for gene therapy applications
9. Neiker-Tecnalia makes progress in detection and prevention of infection by visna maedi virus
10. Measles virus plays role in Pagets disease of bone, Pitt-led team says
11. Measles virus, a weapon against cancer?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... have shown the potential for global climate change to ... most part, ignored the interactions between increasing temperature and ... to damage crops. , A new study involving researchers ... significant, suggesting that policymakers need to take both warming ... , The study looked in detail at global production ...
(Date:7/27/2014)... scientists have identified more than two dozen genetic ... that had not been previously reported. The study, ... funded by the National Institutes of Health (NIH) ... , "Unraveling the genetic underpinnings of Parkinson,s is ... this complex disease, and hopefully, may one day ...
(Date:7/25/2014)... burn scars on this false-color image from the Terra satellite ... year,s rash of wildfires in Eastern Russia. The burn ... green background. The wildfires have broken across the remote ... in this false-color image from the MODIS instrument, it ... fires that continue. Two recent image features noted below show ...
Breaking Biology News(10 mins):Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... A research team, led by Institute of Zoology ... reconstructed a continuous population history of the giant panda ... whereas global changes in climate were the primary drivers ... activities were likely to underlie recent population divergence and ...
... the IOF Regionals Asia-Pacific Osteoporosis Meeting, researchers from the ... Health, announced a study which links carotenoids to decreased ... who are lean (BMI In the study, ... and hip fracture risk across a range of BMI ...
... to crizotinib gaining approval for the treatment of advanced ... the United States, Canada, and several other countries in ... therapy for ALK-positive NSCLC places great emphasis on rapid, ... subtype of lung cancer. A recent study published in ...
Cached Biology News:Chinese scientists discover evidence of giant panda's population history and local adaptation 2Chinese scientists discover evidence of giant panda's population history and local adaptation 3Study shows immunohistochemistry is reliable screening tool for ALK rearrangement 2
(Date:7/28/2014)... (PRWEB) July 28, 2014 Proove ... medicine, will be exhibiting data and research conducted through ... International Spine Intervention Society’s (ISIS) 22nd Annual Scientific ... at the Hyatt Regency, in Orlando, Florida. ... and clinical competence of physicians who care for patients ...
(Date:7/28/2014)... July 28, 2014 /PRNewswire/ -   JOLT , a ... companies to join its growing portfolio of startups. Next-level ... Toronto,s JOLT accelerator, and Cohort four ... roster. Since its launch in July ... raised  $7.5M of financing. Now at 23 investments, JOLT,s ...
(Date:7/28/2014)... 28, 2014  David Hardison, Ph.D., vice president ... , has been elected chairman of the board ... non-profit working to establish common protocols around the ... relates to electronic health records. ... collaborating with organizations across the research and health ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health , ... announced the hire of Brad Towle as ... be responsible for driving the company,s sales growth, customer ... in healthcare, and specifically his past role in the ... the company at this pivotal time in the industry," ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... BRISBANE, Calif. , May 4 InterMune, Inc. (Nasdaq: ... issued a complete response letter for the New Drug Application (NDA) for ... to reduce decline in lung function. , ... A complete response letter is issued by the FDA,s Center ...
... Calif. , May 4 S*BIO Pte Ltd and Onyx ... development collaboration and option and license commercialization agreement for S*BIO,s novel JAK2 ... respectively. The expanded agreement builds upon the development and commercialization collaboration between ... , , ...
... Fla. , May 4 Romark Laboratories announced results ... of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. ... a late breaking forum of the American Gastroenterological Association Institute (AGA ... . , , , ...
Cached Biology Technology:InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 2InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 3InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 4InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 5S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 2S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 3S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 4S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 5Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 2Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 3Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 4Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 5
...
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
Handles samples from from 75l to 150l...
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Biology Products: